Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The cash consideration for the acquisition is US$ 18 million.
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Subscribe To Our Newsletter & Stay Updated
